Laboratory Table of Contents

Regence Logos

Search:

» Medical Policy

» Medication Policy

» Dental Policy

» Clinical Position Statements

» Practice Guidelines

» Uniform Glossary of Terms

Laboratory Section

Policy Name	Date Modified
Allergy Tests of Uncertain Efficacy	03/20/2013
Analysis of Proteomic Patterns for Early Detection of Cancer	03/01/2013
Biochemical Markers of Alzheimer's Disease	01/01/2013
Bone Turnover Markers for Diagnosis and Management of Osteoporosis	09/01/2012
Detection of Circulating Tumor Cells in the Management of Patients with Cancer	01/01/2013
In-Vitro Chemoresistance and Chemosensitivity Assays	06/01/2012
Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5-Flurouracil (5-FU) Dosing for Patients Adminstered 5-FU for Cancer	02/01/2013
Laboratory Tests for Heart Transplant Rejection	08/01/2012
Measurement of Lipoprotein-Associated Phospholipase A2 Lp-PLA2) in the Assessment of Cardiovascular Risk	03/01/2013
Placental Rapid Immunoassay for detection of Fetal Membrane Rupture (AmniSure® and ROM Plus® Tests)	11/01/2012
Salivary Hormone Testing for Aging and Menopause	04/01/2013
Serum Holo-Transcobalamin as a Marker of Vitamin B12 (i.e., Cobalamin) Status	05/01/2013
Systems Pathology for Predicting Risk of Recurrence in Prostate Cancer	07/01/2012
Vitamin D Testing	05/01/2013


	The Blue Cross and/or Blue Shield Plans comprising The Regence Group serve Idaho, Oregon, Utah and much of Washington state. The Regence Group and each of its affiliate Plans are independent licensees of the Blue Cross and Blue Shield Association.